Advertisement
Singapore markets open in 8 hours 2 minutes

  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     

  • S&P 500

    5,192.93
    +12.19 (+0.24%)
     

  • Dow

    38,894.48
    +42.21 (+0.11%)
     

  • Nasdaq

    16,373.03
    +23.78 (+0.15%)
     

  • Bitcoin USD

    63,557.28
    +305.21 (+0.48%)
     

  • CMC Crypto 200

    1,316.87
    -48.26 (-3.53%)
     

  • FTSE 100

    8,313.67
    +100.18 (+1.22%)
     

  • Gold

    2,321.90
    -9.30 (-0.40%)
     

  • Crude Oil

    78.78
    +0.30 (+0.38%)
     

  • 10-Yr Bond

    4.4370
    -0.0520 (-1.16%)
     

  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     

  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     

  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     

  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     

  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

Analyst Ratings for Endo International and Peers in August

Margaret Patrick
Updated
Analyst Ratings for Endo International and Peers in August

In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.

Continue reading